Mesalazine Treatment in IBS (The MIBS Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2016

Study Completion Date

February 28, 2017

Conditions
Irritable Bowel Syndrome
Interventions
DRUG

Mesalazine

2400 mg q.d. for 8 weeks

DRUG

Placebo

3 tablets q.d. for 8 weeks

Trial Locations (3)

Unknown

Sahlgrenska University Hospital, Gothenburg

Karolinska University Hospital, Huddinge

Norrland's University Hospital, Umeå

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sahlgrenska University Hospital

OTHER

collaborator

Smerud Medical Research International AS

OTHER

collaborator

Alimenta AB

UNKNOWN

collaborator

Tillotts Pharma AG

INDUSTRY

collaborator

Karolinska University Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Oslo University Hospital

OTHER

collaborator

Sykehuset Innlandet HF

OTHER

lead

Hans Törnblom

OTHER

NCT01699438 - Mesalazine Treatment in IBS (The MIBS Study) | Biotech Hunter | Biotech Hunter